Thu, 4 May 2017
Manufacturing pharmaceuticals has long been a highly profitable business. But there were risks involved, high costs for research and development for drugs that might never work, or find a market. But now, we have vulture pharma manufacturers, who buy old companies, dump all the expensive R&D and jack prices sky-high. Investigative reporter Roddy Boyd on the rise and fall of Valeant the king of the vultures. Wall Street loved this predatory model, and now some of the fattest hedge fund hogs are out billions of dollars.